05/08/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/30/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/04/2024
5:30 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/02/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/29/2024
1:30 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/22/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/21/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
03/20/2024
7:07 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/08/2024
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/05/2024
8:30 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/21/2023
6:35 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/20/2023
4:30 PM | OKYO Pharma (Filer)
| Form 424B5 | |
12/18/2023
3:56 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/04/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/29/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/01/2023
3:55 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/31/2023
3:59 PM | OKYO Pharma (Filer)
| Form 424B5 | |
10/31/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/10/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/05/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/28/2023
5:15 AM | BRANCACCIO JOHN P (Reporting)
OKYO Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/15/2023
3:05 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/15/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/15/2023
5:05 AM | OKYO Pharma (Filer)
| Form 424B5 | |
09/14/2023
9:03 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/14/2023
9:05 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/13/2023
3:05 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/13/2023
3:13 PM | OKYO Pharma (Filer)
| Form 424B5 | |
09/08/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/30/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/29/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/25/2023
10:33 AM | OKYO Pharma (Filer)
| Form 20-F/A | |
08/15/2023
8:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/31/2023
5:02 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/28/2023
4:24 PM | OKYO Pharma (Filer)
| Form 424B5 | |
07/28/2023
4:25 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/28/2023
4:25 PM | OKYO Pharma (Subject)
| Form FWP | |
07/28/2023
4:05 PM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/28/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
This Apple-like Innovator is Revolutionizing Healthcare (Ad) AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing.
Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry |
06/15/2023
3:10 PM | OKYO Pharma (Filer)
| Form 424B3 | |
06/14/2023
11:15 PM | OKYO Pharma (Filer)
| Form EFFECT | |
06/14/2023
11:15 PM | OKYO Pharma (Filer)
| Form EFFECT | |
06/08/2023
3:31 PM | OKYO Pharma (Filer)
| Form F-1/A | |
06/06/2023
8:30 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/02/2023
4:30 PM | OKYO Pharma (Filer)
| Form F-1/A | |
05/22/2023
6:00 AM | OKYO Pharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
